Gyre Therapeutics Inc (GYRE) Stock Price, Quote & News

Company Profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 949 3681

Website: www.gyretx.com

Address:

12770 High Bluff Drive, Suite 150, San Diego, United States

Whales22 Oct. 23 at 7:01 AM

$TERN $HCTI $GYRE $NBY How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI

0 · Reply

Thestocktraderhubzee Oct. 15 at 11:18 AM

$GYRE Gyre Therapeutics Has Completed Patient Enrollment In The 52-week Phase 3 Trial In China Of Pirfenidone Capsules, For Pneumoconiosis

0 · Reply

MilsLearning Oct. 13 at 8:04 AM

$GYRE "L"ets "F" "S"horts 🩳🔥🩳🔥🩳🖕🩳🖕🩳🖕🔜🕖✅ Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***

0 · Reply

Godwins26 Oct. 10 at 10:10 PM

7th Watchlist for the week 😊 $EPWK $YGMZ $DVLT $GYRE $ORBS

1 · Reply

notreload_ai Oct. 10 at 1:27 PM

Jefferies began coverage of $GYRE with a Buy rating and a $16 price target. The company is growing in China, aiding its pipeline progress. The lead asset Hydronidone 's Phase 3 study in chronic hepatitis B may lead to a first-in-class launch in China in 2026.

0 · Reply

JarvisFlow Oct. 10 at 11:28 AM

Jefferies updates rating for Gyre Therapeutics ( $GYRE ) to Buy, target set at 16.

0 · Reply

JohnnyArtis200 Sep. 22 at 6:22 AM

$GYRE Marine services cyclicality. Testing support level. Volume decline concerning. Sector headwinds.

0 · Reply

NetworkNewsWire Sep. 9 at 3:57 PM

BioMedNewsBreaks — $GYRE Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone https://ibn.fm/9wCTA

0 · Reply

Channelchek Sep. 9 at 1:50 PM

Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Positioned To End YE2025 With Strong Products and Pipeline Development Gyre Has Made Strong YTD Progress. Gyre has made significant progress during the first three quarters of FY2025 that we believe positions the company for a strong year-end. These developments include continued sales growth from two products introduced in 1H25, an application for Hydronidone approval in China, and the start of a Phase 2 clinical trial for Hydronidone in the US. The company also announced the appointment of Dr. Han Ying as the new CEO, a member of the Board of Directors since January 2025. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-positioned-to-end-ye2025-with-strong-products-and-pipeline-development

0 · Reply

Arya3t Aug. 31 at 2:57 AM

HuiopkloiuytrewQA $GYRE

0 · Reply

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

Oct 14, 2025, 7:00 AM EDT - 11 days ago

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

Sep 5, 2025, 4:05 PM EDT - 7 weeks ago

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 2:53 PM EDT - 2 months ago

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Aug 22, 2025, 7:00 AM EDT - 2 months ago

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

May 29, 2025, 4:01 PM EDT - 5 months ago

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 22, 2025, 8:57 PM EDT - 5 months ago

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

May 22, 2025, 4:02 PM EDT - 5 months ago

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

May 22, 2025, 4:01 PM EDT - 5 months ago

Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

May 9, 2025, 6:00 AM EDT - 6 months ago

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 31, 2025, 7:00 AM EDT - 7 months ago

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Mar 27, 2025, 7:00 AM EDT - 7 months ago

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Mar 17, 2025, 4:15 PM EDT - 7 months ago

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Nov 13, 2024, 6:00 AM EST - 1 year ago

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Oct 1, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Aug 13, 2024, 6:00 AM EDT - 1 year ago

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

May 30, 2024, 4:05 PM EDT - 1 year ago

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

May 28, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

May 9, 2024, 4:10 PM EDT - 1 year ago

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Mar 26, 2024, 6:00 AM EDT - 1 year ago

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Dec 15, 2023, 9:04 AM EST - 2 years ago

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Nov 13, 2023, 7:00 AM EST - 2 years ago

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

Whales22 Oct. 23 at 7:01 AM

$TERN $HCTI $GYRE $NBY How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI

0 · Reply

Thestocktraderhubzee Oct. 15 at 11:18 AM

$GYRE Gyre Therapeutics Has Completed Patient Enrollment In The 52-week Phase 3 Trial In China Of Pirfenidone Capsules, For Pneumoconiosis

0 · Reply

MilsLearning Oct. 13 at 8:04 AM

0 · Reply

Godwins26 Oct. 10 at 10:10 PM

7th Watchlist for the week 😊 $EPWK $YGMZ $DVLT $GYRE $ORBS

1 · Reply

notreload_ai Oct. 10 at 1:27 PM

0 · Reply

JarvisFlow Oct. 10 at 11:28 AM

Jefferies updates rating for Gyre Therapeutics ( $GYRE ) to Buy, target set at 16.

0 · Reply

JohnnyArtis200 Sep. 22 at 6:22 AM

$GYRE Marine services cyclicality. Testing support level. Volume decline concerning. Sector headwinds.

0 · Reply

NetworkNewsWire Sep. 9 at 3:57 PM

BioMedNewsBreaks — $GYRE Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone https://ibn.fm/9wCTA

0 · Reply

Channelchek Sep. 9 at 1:50 PM

0 · Reply

Arya3t Aug. 31 at 2:57 AM

HuiopkloiuytrewQA $GYRE

0 · Reply

MalwareOfMarkets Aug. 29 at 4:12 PM

$GYRE god damm waineright buy rating dropping now

0 · Reply

JarvisFlow Aug. 26 at 11:30 AM

HC Wainwright & Co. updates rating for Gyre Therapeutics ( $GYRE ) to Buy, target set at 18.

0 · Reply

MalwareOfMarkets Aug. 13 at 10:45 PM

$GYRE and 8.27

0 · Reply

MalwareOfMarkets Aug. 7 at 3:35 PM

$GYRE now 7.27

0 · Reply

MalwareOfMarkets Aug. 1 at 7:45 PM

$GYRE now 666 lucky number?

0 · Reply

Slowhorses Jul. 23 at 8:59 PM

$ALAR or $GYRE or $ SEMR ??? Any thoughts please which one to go ?

0 · Reply

BrielleX_619 Jul. 9 at 1:49 PM

$GYRE ⁨WKSP: U.S. factory ✅ 50%+ prod growth ✅ Doubling margins ✅ Nano-grid + solar Q3 rollout ✅ 1K-truck federal pilot ✅ No China exposure 🔥EYES ON $7+⁩

0 · Reply

Ayed91 Jun. 21 at 1:52 PM

$GYRE

0 · Reply

topstockalerts Jun. 17 at 1:45 PM

$GYRE not a bad place for a swing idea 💡💡💡

0 · Reply

Razz_FluidX2 Jun. 17 at 12:42 PM

$GYRE

0 · Reply

CyrusLopez5 Jun. 16 at 7:49 PM

$AMD $BTC.X $XRP.X $GYRE Analyst price target for today🚀 https://lked.in/options-chat-live

0 · Reply

Market Cap	786.88M
Revenue (ttm)	105.76M
Net Income (ttm)	12.09M
EPS (ttm)	N/A
PE Ratio	164.60
Forward PE	63.31
Profit Margin	11.43%
Debt to Equity Ratio	0.00

Volume	43,900
Avg Vol	96,816
Day's Range	N/A - N/A
Shares Out	96.31M
Stochastic %K	25%
Beta	1.78
Analysts	Sell
Price Target	$18.00